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RESUMO – Introdução: A fototerapia é uma terapêutica bem consolidada no tratamento da psoríase, com uma relação risco-
-benefício bastante favorável. A fotoquimioterapia envolve a administração de psoraleno per os (PUVA oral) ou tópico (banho 
PUVA), antes da irradiação por UVA. A administração oral de psoraleno pode causar efeitos adversos, enquanto o banho PUVA 
tem a vantagem de diminuir a toxicidade sistémica e os efeitos adversos do psoraleno. O nosso estudo teve como principal ob-
jectivo comparar a eficácia entre as duas modalidades de PUVA. Material e Métodos: Estudo retrospetivo, aplicado aos doentes 
com psoríase em placas tratados com PUVA no nosso serviço de Dermatologia, entre janeiro 2001 e dezembro 2016. Resul-
tados: Foram realizados 81 ciclos de tratamentos com PUVA oral e 38 com banho PUVA, correspondendo a 68 e 26 doentes, 
respetivamente. A idade média foi de 50,6 anos. No primeiro grupo, o PASI 75 foi atingido em 68 casos (89,5%), e no grupo 
de banho PUVA em 26 (74,3%), com p = 0,05. A dose média para atingir o PASI 75 no grupo PUVA oral foi de 113,1 J/cm2 
e no grupo banho PUVA de 69,8 J/cm2. No grupo PUVA oral, o número médio de sessões realizadas para atingir PASI 75 foi 
de 23,31, e no grupo banho PUVA 17,58. Conclusão: Embora exija equipamento especializado e mais tempo de execução, 
o banho PUVA pode ser considerado ainda um dos tratamentos mais eficazes na psoríase, sobretudo num grupo particular de 
doentes não candidatos a terapêuticas sistémicas.
PALAVRAS-CHAVE – Administração Oral; Administração Tópica; Banhos; Psoríase/tratamento; Terapia PUVA.
Oral PUVA Versus Bath PUVA in Chronic Plaque 
Psoriasis: A Comparative Study of Efficacy   
ABSTRACT – Introduction: Phototherapy has long been recognized as beneficial for psoriasis treatment, with a favorable risk-
-benefit relation. Photochemotherapy comprises the use of psoralen, either orally (oral PUVA) or topically (bath PUVA), prior to 
UVA irradiation. Oral administration of psoralen may lead to short or long-term side effects. Bath PUVA is particularly useful to 
minimize systemic toxicity and psoralen side effects. The aim of this study was to compare the effectiveness of these two PUVA 
modalities. Material and Methods: A retrospective review of patients with chronic plaque psoriasis treated with PUVA therapy 
(oral and bath) in our dermatology department, between January 2001 and December 2016. Results: We performed 81 treat-
ments with oral PUVA and 38 treatments with bath PUVA, in 68 and 26 patients, respectively. The mean age of the patients was 
50,6 years. Oral PUVA group achieved PASI 75 in 68 cases (89.5%), and bath PUVA group in 26 (74.3%), with p-value=0 .05. 
The mean total dose needed to achieve PASI 75 in the oral PUVA group was 113.1 J/cm2 and in the bath PUVA group was 69.8 
J/cm2. The mean number of sessions performed to achieve remission in the oral PUVA group was 23.31, and in the bath PUVA 
group was 17.58. Conclusion: Despite requiring specialized equipment and being more time consuming, bath PUVA represents 
one of the most effective therapies available for psoriasis and it should be considered as a treatment option for patients who are 
not candidates for systemic treatment.
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INTRODUCTION
Phototherapy is a well-known treatment for several 
cutaneous inflammatory diseases. In psoriasis, photo-
therapy has a particularly favorable risk-benefit relation. 
However, the use of phototherapy/photochemotherapy in 
dermatologic departments has declined because of logistic 
issues and the development of new systemic drugs. 
The mechanisms of the action of phototherapy in pso-
riasis include an effect on cell surface receptors with modi-
fication of the cytokine profile and secretion of mediators 
with anti-inflammatory and immunosuppressive properties, 
antiproliferative effects and induction of apoptosis in target 
and effector cells, such as epidermal and dermal T cells, 
keratinocytes and also to a lesser extent Langerhans cells.1
Photochemotherapy includes the administration of a 
psoralen, which is a photoactive furocoumarin that after 
UV irradiation binds both DNA chains, interfering with the 
process of cell division, thus enhancing the effect of pho-
totherapy. Psoralen can be administered either orally (oral 
PUVA) or topically (bath PUVA), prior to irradiation in the 
UVA cabin. Oral administration of psoralen may lead to 
nausea or long-term side effects (cataracts, skin tumors, 
skin aging). Bath PUVA is particularly useful to minimize 
psoralen systemic toxicity and side effects.2-5 The above-
mentioned advantages of bath PUVA motivated us to study 
and compare this treatment modality with more widely 
used oral PUVA.
MATERIAL AND METHODS
We conducted a retrospective review of the patients with 
plaque psoriasis treated with PUVA therapy (oral and bath) 
in our dermatology department, between January 2001 
and December 2016. 
Treatment protocol: The oral PUVA group received 
8-methoxypsoralen capsules (0.3-0.5 mg/kg) 2 hours 
prior to UVA irradiation. Patients treated with bath PUVA 
were immersed during 15 minutes in a 0.5 mg/L solution 
of 8-methoxypsoralen, followed by UVA irradiation within 
minutes. In both groups, the initial UVA dose was 0.5 J/cm2 
and the dose was increased by 0.5 J/cm2 with each ses-
sion. Both oral PUVA patients and bath PUVA patients were 
treated 3 times per week until complete clearing.
PASI score was used to assess disease severity and eva-
luate efficacy of therapy. Achievement of PASI 75 (75% 
reduction in the PASI score), considered a successful outco-
me. The 2 groups were compared concerning the number 
of UV sessions and UV dose needed to reach a PASI 75, as 
well as the length of duration of treatment response. 
Statistical analysis was performed with SPSS Statistics (v. 
23; IBM SPSS). The sample was characterized by descriptive 
and inferential statistical methods. Means were compared 
by the Student t-test when the conditions of normality and 
homogeneity of variances were fulfilled. For the analysis of 
2 independent samples, without normal distribution, the 
Mann-Whitney U test was used to compare the medians. 
Nominal data were analyzed by Pearson's χ2 test and, in 
situations with low number of cells, Fisher's exact test was 
used. Statistical  significance was considered when p-value 
was equal or below 0.05.
The local hospital ethics committee and the Portuguese 
National Data Protection authority approved the study.
RESULTS
We performed 81 treatments with oral PUVA and 38 
treatments with bath PUVA, in 68 and 26 patients, respec-
tively. The mean age of the patients was 50.6 years (SD = 
12.84 years) (49.9 years in the oral PUVA group versus 
52.0 years in the bath PUVA group). 
The mean initial psoriasis area and severity index (PASI) 
was similar in both groups, 21.0 in oral PUVA group and 
22.5 in bath PUVA group, expressing the moderate to high 
disease severity within the entire sample of treated patients. 
Oral PUVA group achieved PASI 75 in 68 cases (89.5%), 
and bath PUVA group in 26 (74.3%), with a p-value = 
0.05. The inferential statistical analysis showed that the 
effectiveness of PUVA is independent of the treatment mo-
dality. 
The mean total dose needed to achieve PASI 75 was 
113.1 J/cm2 (median 97.5) in oral PUVA group and 69.8 
J/cm2 (median 46.2) in bath PUVA group, p = 0.001 (Fig. 
1). The mean number of sessions performed to achieve re-
mission was 23.31 (SD = 8.5) in the oral PUVA group, and 
17.58 (SD = 10.0) in the bath PUVA group, p = 0.008. In 
bath PUVA group, PASI 75 was achieved with 1.5 to 9.94 
less sessions (in average 5.7 sessions), comparing to oral 
PUVA group. 
The study evaluated also remission duration, i.e. inter-
val between the complete or almost complete clearance and 
the reappearance of lesions. The study sample was divided 
into 4 groups according to remission interval: 1 to 3 months, 
3.5 to 6 months, 6.5 to 12 months and remission for more 
than 12 months. Comparing the oral PUVA group with bath 
PUVA group, there was no difference in remission intervals 
in both groups (p = 0.766). The results are summarized in 
the Table 1.
Figure 1 - Diagram of extremes and quartiles for the dose of UVA 
administered in oral PUVA group (n=81) and bath PUVA group (n=38).
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DISCUSSION
The present study confirmed the effectiveness of PUVA 
in the treatment of psoriasis.6 Comparing the two treatment 
modalities, bath and oral PUVA, we found equal/similar 
efficacy. There are few studies comparing efficacy of the 
two PUVA treatment modalities in chronic plaque psoriasis. 
The only prospective randomized trial comparing the effi-
cacy of oral and bath PUVA, conducted by Berneburg et al 
in 2013, concluded overall excellent effectiveness of PUVA 
with no difference in the two studied groups.6 Other smal-
ler, comparative studies showed similar effectiveness of bath 
and systemic PUVA, nonetheless, as in our work, the studies 
highlight that patients treated with bath PUVA required an 
inferior number of sessions and less total dose to clear the 
lesions.7-11 Additionally, patients who fail to respond to oral 
PUVA may benefit from switching to bath PUVA.10 However, 
in the studies no standard methodology has been used, na-
mely in terms of psoralen concentration used for bath PUVA 
(0.4 mg/L, 1 mg/L, 3.7 mg/L to 4.6 mg/L). Psoralen con-
centration used in our study was 0.5 mg/L, which despite 
of being lower than in most studies still lead to significant 
effectiveness.
Attending to patients´ preferences, there might be sli-
ght tendency to bath PUVA when the patient is involved in 
the treatment modality decision. Alshiyab et al studied the 
treatment preferences in 99 patients treated with photoche-
motherapy. Of the whole group, 55% preferred bath PUVA, 
with a clearer preference among females (61%). Moreover, 
within the subgroup of patients that had previously received 
bath PUVA therapy, 75% preferred to be treated again with 
bath PUVA.7,11
Safety of bath PUVA was highlighted in several studies.4-8 
Skin cancer, the well-known long term side effects of oral 
PUVA, was investigated in an analysis of a Scandinavian 
population treated with bath PUVA. The authors did not find 
an increased risk of skin cancer with bath PUVA, therefore 
suggesting this an important advantage of bath PUVA over 
oral PUVA.4,5 Topical administration of psoralen may still 
cause immediate or short-term side effects, similarly to oral 
PUVA, such as erythema, blistering and hyperpigmentation. 
In our revision, due to the design of the study, it was not 
possible to access the short- and long-term cutaneous side 
effects in the sample. 
The list of advantages of bath PUVA continues. Patients 
with comorbidities such as hepatic dysfunction, ocular disea-
se or concomitant medication interfering with oral psoralen, 
such as warfarin, may benefit particularly from topical psora-
len use.6-8,12 Furthermore, in patients with moderate to seve-
re plaque psoriasis who present contraindication to biologic 
treatment, such as history of cancer or demyelinating disea-
se, bath PUVA may represent a good therapeutic option. 
Pointing out all the advantages of bath PUVA to oral 
PUVA, one must not forget the logistic issues of bath the-
rapy. This treatment modality requires specific equipment, 
such as a proper room with bathtub and trained health care 
personnel. Also, bath PUVA is more time consuming in com-
parison to oral PUVA and may not be suitable for patients 
with decreased mobility.
CONCLUSION
Bath PUVA, as one of the most effective therapies avai-
lable for psoriasis, is still commonly used in Scandinavian 
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Table 1 - Results of the study highlighting the differences between the two treatment groups. 
Total sample Oral PUVA Bath PUVA p-value
Course of treatments 119 81 38
Age 50.6 (±12.84) 49.9 (±14.3) 52.0 (±9.15) 0.356*
PASI 21.6 (9.5) 21.0 (10.0) 22.5 (8.8) 0.432*
UVA dose (J/cm2)
99.3 (7.1)
Me=81
113.1 (8.9)
Me=97.5
69.8 (10.4)
Me=46.2
0.001*
No. of sessions per course 21.0 (9.6) 23.31 17.58 0.008**
Efficacy (PASI 75) 94 (84.7%) 68 (89.5%) 26 (74.3%) 0.050#
Remission duration
1 to 3 months
3.5 to 6 months
6.5 to 12 months
> 12 months
n=14 (17.1%)
n=25 (30.5%)
n=25 (30.5%)
n=18 (22.0%)
n=12 (20.0%)
n=15 (25.0%)
n=18 (30.0%)
n=15 (25.0%)
n=2 (9.1%)
n=10 (45.5%)
n=7 (31.8%)
n=3 (13.6%)
0.766*
# Fisher's exact test (1 sample); * Mann-Whitney U test (2 independent samples without normal distribution); ** T test for 
equal means, bilateral significance.
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countries for moderate to severe plaque psoriasis in order 
to reduce the systemic psoralen toxicity. In Portugal there are 
few hospital facilities equipped with bathtub for bath PUVA. 
To the best of our knowledge, our department of Dermato-
logy is the only in Portugal who continues using bath PUVA 
for chronic plaque psoriasis, especially for patients with as-
sociated comorbidities. Even if we take into consideration 
the special equipment and more time consuming character 
of bath PUVA treatment, its benefits clearly outweigh these 
minor logistic issues. As a result, we strongly recommend 
bath PUVA treatment for patients with chronic plaque pso-
riasis who are not candidates for systemic treatment. 
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